CROSS Inferior to FLOT in Patients With Esophageal Adenocarcinoma

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the ESOPEC trial, which compared the neoadjuvant CROSS protocol (41.4Gy plus carboplatin/paclitaxel) to the perioperative FLOT protocol (5-FU/leucovorin/oxaliplatin/docetaxel) in patients with resectable locally advanced esophageal adenocarcinoma. This abstract will be presented as LBA1 during the Plenary Session at the 2024 ASCO Annual Meeting. Read the full abstract: meetings.asco.org/abstracts-presentations/234899 For more on ASCO24, visit dailynews.ascopubs.org/meetin...

• #education
• #cancer
• #cancer_care
• #health_care
• #oncology
• #american_society_of_clinical_oncology
• #asco
• #asco24